High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trialAndrés JM Ferreri, Franco Cavalli, Michele Reni et al.|The Lancet|2009Cited by 665
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOPAlexandar Tzankov, Ken H. Young, Zijun Y. Xu‐Monette et al.|Modern Pathology|2013Cited by 129
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOPZijun Y. Xu‐Monette, Ken H. Young, Bouthaina S. Dabaja et al.|Modern Pathology|2015Cited by 54
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapyZhiyu Liu, Ken H. Young, Zijun Y. Xu‐Monette et al.|Modern Pathology|2015Cited by 27
Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival AnalysisAndrés JM Ferreri, Franco Cavalli, Michele Reni et al.|Blood|2008Cited by 7